{"entity":{"id":"nct06283719","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P","aka":[],"tldr":"A phase 1/2 trial of ZG006 in small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","summary":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06283719 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 265 participants planned, started 2024-09-02 and due to reach its primary completion in 2026-04. Interventions recorded: ZG006. Conditions listed: Small Cell Lung Cancer, Neuroendocrine Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06283719","url":"https://clinicaltrials.gov/study/NCT06283719"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["zg006"],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06283719","phase":"1/2","setting":"A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","participation":[{"nct":"NCT06283719","source":"https://clinicaltrials.gov/study/NCT06283719","fetchedAt":"2026-10-07T16:54:29.928Z","studySha256":"65d66b2b4a8ab94b4dd66bdcd14d32c0db2994a74317def0969e90954e3cf59a","overallStatus":"RECRUITING","lastUpdatePosted":"2025-11-17","leadSponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":265,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-09-02","startedType":"actual","enrolled":265,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06283719/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}]}}